Isomerase Therapeutics announces closure of successful second round of seed investment

 November 30th, 2013--Cambridge

Isomerase Therapeutics Ltd. announces that it has closed a second round of seed investment. Isomerase is a drug discovery company based in Cambridge, UK which is developing second-generation biosynthetic engineering technologies and offers collaborations in this and related fields.
CEO of Isomerase Therapeutics, Dr Matt Gregory commented "We have had a very successful first few months of operation, and already have a number of exciting collaborations underway. This investment will enable us to continue to develop our next-generation synthetic biology tools which are fast and efficient to use and we are confident will continue the current revitalisation of natural products drug discovery."

Cookies user preferences
All essential cookies are mandatory in order to allow logging in and submitting forms etc. You can choose to decline some non-essential ones.
Accept all
Decline all
Read more
Tools used to analyze the data to measure the effectiveness of a website and to understand how it works.